1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Martín M, Guerrero-Zotano AL, Pérez-López ME, Ruiz-Borrego M, Martinez Jañez N, Chacón JI, Gil-Gil M, Andrés R, Bermejo B, Sánchez-Rovira P, Del Barco S, Ponce JJ, Fernandez I, Martínez de Dueñas E, Hinojo-Gonzále C, González M, García-Garre E, Hernando B, de la Haba-Rodriguez J, Álvarez IM, González-Santiago S, Garcia-Saenz JA, Santaballa A, Casas M, Bezares S, Caballero R, Rojo F, Alba E.

    Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

    CLINICAL CANCER RESEARCH . 32(5): 850-858. Nº de citas: 4

    [doi:10.1158/1078-0432.CCR-25-2435]

  • Ruz-Caracuel I, Rosell A, Geryková L, Gama JM, Alonso-Gordoa T, Rodríguez-Villena A, Almeida R, Rosas M, Martínez-Hernández R, Martins MJ, Ryska A, Eloy C, Palacios J.

    Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma

    ENDOCRINE PATHOLOGY . 36(1): 49-49. Nº de citas: 4

    [doi:10.1007/s12022-025-09894-9]

  • Araujo-Castro M, Menéndez Torre E, Aida CL, García-Centeno R, González L, Idrobo C, Achote E, Irigaray Echarri A, Rodríguez-Argulló MDM, Paja M, Guerrero-Pérez F, Castaño JP, Dolores Ollero García M, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabeu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Martín-Rojas P, Recio-Córdova JM, Aulinas A, Asla Roca Q, Aviles MD, López Mezquita E, Fernández Argüeso M, González Molero I, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.

    Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(12): 3391-3399. Nº de citas: 13

    [doi:10.1210/clinem/dgaf252]

  • Biagetti B, Cardona-Arias A, Torre EM, Aulinas A, Ruz-Caracuel I, Centeno RG, González L, Echarri AI, Rodríguez MDM, Paja M, Guerrero-Pérez F, Castaño JP, García MDO, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabéu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Rojas-Marcos PM, Recio-Córdova JM, Lozano-Aida C, Roca QA, Aviles MD, Mezquita EL, Argueso MF, Molero IG, Alberoa I, Idrobo C, Achote E, Martínez-Sáez E, Marazuela M, Puig-Domingo M, Hanzu F, Araujo-Castro M.

    Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study

    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION . 48(12): 2857-2867. Nº de citas: 5

    [doi:10.1007/s40618-025-02674-6]

  • Martínez-Hernández R, Méndez-García FF, Serrano-Somavilla A, Sacristán-Gómez P, Sánchez de la Blanca N, Sampedro-Núñez M, Navas-Moreno V, Sebastián-Valles F, Fernández-Alen JA, Biagetti B, Ruz-Caracuel I, Araujo-Castro M, Puig-Domingo M, Marazuela M.

    Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . : . Nº de citas: 3

    [doi:10.1210/clinem/dgaf634]

  • Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, Garcia-Carbonero R, Teulé A, Custodio A, Jimenez-Fonseca P, Lopez C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, Garcia-Alvarez A, Alonso-Gordoa T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E.

    Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

    CLINICAL CANCER RESEARCH . 31(22): 4655-4663. Nº de citas: 4

    [doi:10.1158/1078-0432.CCR-25-2143]

  • Martinez-Jañez N, García-Saenz JÁ, Pernas S, Bermejo B, Morales S, Guerra J, Silva J, Manso L, Ciruelos E, Tolosa P, Sánchez-Bayona R, Alva M, Calabuig-Fariñas S, Gallach S, Muinelo-Romay L, Piñeiro-Yáñez E, Caleiras E, Bueno MJ, Mouron S, Quintela-Fandino M.

    Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

    npj Precision Oncology . 9(1): 343-343. Nº de citas: 4

    [doi:10.1038/s41698-025-01106-1]

  • Carmona-Bayonas A, Álvarez Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez Trufero J, Febrero Sánchez B, Saiz López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P.

    Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(11): 3155-3167. Nº de citas: 3

    [doi:10.1210/clinem/dgaf082]

  • Smith M, Piulats J, Todenhöfer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Fléchon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N.

    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    LANCET ONCOLOGY . 26(11): 1489-1500. Nº de citas: 3

    [doi:10.1016/S1470-2045(25)00475-9]

  • Madariaga A, Cots M, Hierro C, Robles C, Garrido S, Barretina-Ginesta MP, Serrano A, Serena M, Salcedo P, Mariátegui N, Guerra E.

    Needs and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain

    Clinical & Translational Oncology . : . Nº de citas: 1

    [doi:10.1007/s12094-025-04127-1]

  • Lopez-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjón A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de Los Rios V, Redondo A, Pelaez-Garcia A, Hardisson D.

    The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas

    Cells . 14(21): . Nº de citas: 2

    [doi:10.3390/cells14211676]

  • Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.

    Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer

    LABORATORY INVESTIGATION . 105(10): 104199-104199.

    [doi:10.1016/j.labinv.2025.104199]

  • Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull-Delgado A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer-Montiel A.

    A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study

    Clinical & Translational Oncology . 28(3): 1040-1048. Nº de citas: 2

    [doi:10.1007/s12094-025-04062-1]

  • Soria A, Díaz A, Iruzubieta P, Martín-Mateos R, Salcedo-Allende MT, Jiménez-Masip A, Fuster-Anglada C, Arias-Loste MT, Perna C, El Maimouni C, Pericas JM, Ferrer-Gómez A, González CJ, Muñoz-Martínez S, Padilla M, Crespo J, Calixto Z, Sabiote C, Albillos A, Cervera M, Olivas I, Arvaniti P, Hernández-Évole H, Jiménez-Esquivel N, Gratacós-Ginès J, Juanola A, Pose E, Coll M, Nadal R, Pérez-Guasch M, Fabrellas N, Ginès P, Londoño MC, Graupera I.

    Autoantibodies are associated with worse outcomes in MASLD

    JHEP Reports . 7(10): 101470-101470. Nº de citas: 3

    [doi:10.1016/j.jhepr.2025.101470]

  • Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A.

    Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation

    JOURNAL OF CLINICAL ONCOLOGY . 43(26): 2908-2917. Nº de citas: 5

    [doi:10.1200/JCO-25-00225]

  • Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.

    A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . : 102654-102654. Nº de citas: 2

    [doi:10.1016/j.ijgc.2025.102654]

  • Manso L, Sánchez-Bayona R, Guerra JA, Cortés-Salgado A, Cejalvo JM, Garcia-Saenz JA, Morales S, González-Cortijo L, Mourón S, Bueno MJ, Garma LD, Quintela-Fandino M.

    A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

    Cancer Research Communications . 5(9): 1728-1737. Nº de citas: 2

    [doi:10.1158/2767-9764.CRC-25-0428]

  • Aguzzi C, De Summa S, Molina-Cerrillo J, Alonso-Gordoa T, Nabissi M, Rizzo M, Zeppellini A, Sunela K, Sorgentoni G, Ortega C, Massari F, Marques Monteiro FS, Battelli N, Porta C, Santoni G, Santoni M.

    mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a)

    Biochemistry and Biophysics Reports . 43: 102162-102162. Nº de citas: 1

    [doi:10.1016/j.bbrep.2025.102162]